Evofem Biosciences (EVFM) Competitors $0.0098 +0.00 (+5.38%) As of 02:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. CMND, GLTO, MTNB, RDHL, DRMA, VIVS, EVOK, TTNP, SNGX, and NBYShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Clearmind Medicine (CMND), Galecto (GLTO), Matinas Biopharma (MTNB), Redhill Biopharma (RDHL), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Evoke Pharma (EVOK), Titan Pharmaceuticals (TTNP), Soligenix (SNGX), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Clearmind Medicine Galecto Matinas Biopharma Redhill Biopharma Dermata Therapeutics VivoSim Labs Evoke Pharma Titan Pharmaceuticals Soligenix NovaBay Pharmaceuticals Clearmind Medicine (NASDAQ:CMND) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Which has better valuation and earnings, CMND or EVFM? Evofem Biosciences has higher revenue and earnings than Clearmind Medicine. Clearmind Medicine is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearmind MedicineN/AN/A-$5.26M-$1.10-0.89Evofem Biosciences$11.39M0.10$52.98M-$0.05-0.20 Is CMND or EVFM more profitable? Clearmind Medicine has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Clearmind Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Clearmind MedicineN/A -164.79% -71.12% Evofem Biosciences -46.42%-91.97%-61.93% Do institutionals and insiders believe in CMND or EVFM? 96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer CMND or EVFM? In the previous week, Clearmind Medicine had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 3 mentions for Clearmind Medicine and 1 mentions for Evofem Biosciences. Clearmind Medicine's average media sentiment score of 0.86 beat Evofem Biosciences' score of -0.99 indicating that Clearmind Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearmind Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has more volatility & risk, CMND or EVFM? Clearmind Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. SummaryEvofem Biosciences beats Clearmind Medicine on 7 of the 12 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.16M$752.28M$5.56B$9.30BDividend YieldN/A4.84%4.23%4.03%P/E Ratio-0.021.4328.6319.67Price / Sales0.1025.50439.23185.66Price / CashN/A19.5636.0257.93Price / Book0.006.658.185.64Net Income$52.98M-$4.53M$3.23B$257.73M7 Day PerformanceN/A1.89%-0.20%0.21%1 Month PerformanceN/A1.70%5.43%8.47%1 Year PerformanceN/A7.59%26.39%13.93% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences1.1192 of 5 stars$0.01+5.4%N/A-2.1%$1.16M$11.39M-0.02120News CoverageGap UpCMNDClearmind Medicine0.9157 of 5 stars$0.99-9.8%N/A-56.2%$4.69MN/A-0.90N/AGap DownGLTOGalecto3.2181 of 5 stars$3.24-8.5%$10.00+208.6%-76.0%$4.68MN/A-0.2140Gap DownMTNBMatinas BiopharmaN/A$0.92+0.3%N/AN/A$4.68MN/A-0.1930RDHLRedhill BiopharmaN/A$2.06+1.5%N/A-99.2%$4.65M$8.04M0.00210Positive NewsDRMADermata Therapeutics2.1915 of 5 stars$0.70+4.7%$3.00+331.7%-66.7%$4.24MN/A-0.048VIVSVivoSim LabsN/A$1.77+12.7%N/AN/A$4.08M$140K-0.1720High Trading VolumeEVOKEvoke Pharma0.8198 of 5 stars$2.65-2.6%N/A-27.5%$4.06M$10.25M-0.924Gap DownTTNPTitan Pharmaceuticals0.3175 of 5 stars$4.45+1.1%N/A-1.3%$4.02M$180K-0.9710SNGXSoligenix2.7599 of 5 stars$1.12-6.7%N/A-81.8%$3.92M-$117.03K-0.2620Analyst ForecastNBYNovaBay Pharmaceuticals1.5759 of 5 stars$0.66+5.4%$0.85+28.2%-69.0%$3.86M$9.78M-0.0130Gap Up Related Companies and Tools Related Companies Clearmind Medicine Alternatives Galecto Alternatives Matinas Biopharma Alternatives Redhill Biopharma Alternatives Dermata Therapeutics Alternatives VivoSim Labs Alternatives Evoke Pharma Alternatives Titan Pharmaceuticals Alternatives Soligenix Alternatives NovaBay Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVFM Stock Alerts